Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

Yuki Yoshimatsu; Noriyuki Ebi; Ryunosuke Ooi; Takuto Sueyasu; Saori Nishizawa; Miyuki Munechika; Kohei Yoshimine; Yuki Ko; Hiromi Ide; Kosuke Tsuruno; Kazunori Tobino

doi:10.2169/internalmedicine.5463-20

CASE REPORTS

Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

Yuki Yoshimatsu, Noriyuki Ebi, Ryunosuke Ooi, Takuto Sueyasu, Saori Nishizawa, Miyuki Munechika, Kohei Yoshimine, Yuki Ko, Hiromi Ide, Kosuke Tsuruno, Kazunori Tobino

著者情報

Yuki Yoshimatsu
Department of Respiratory Medicine, Iizuka Hospital, Japan
Department of Physiology, Hyogo College of Medicine, Japan
Noriyuki Ebi
Department of Respiratory Medicine, Iizuka Hospital, Japan
Ryunosuke Ooi
Department of Respiratory Medicine, Iizuka Hospital, Japan
Takuto Sueyasu
Department of Respiratory Medicine, Iizuka Hospital, Japan
Saori Nishizawa
Department of Respiratory Medicine, Iizuka Hospital, Japan
Miyuki Munechika
Department of Respiratory Medicine, Iizuka Hospital, Japan
Kohei Yoshimine
Department of Respiratory Medicine, Iizuka Hospital, Japan
Yuki Ko
Department of Respiratory Medicine, Iizuka Hospital, Japan
Hiromi Ide
Department of Respiratory Medicine, Iizuka Hospital, Japan
Kosuke Tsuruno
Department of Respiratory Medicine, Iizuka Hospital, Japan
Kazunori Tobino
Department of Respiratory Medicine, Iizuka Hospital, Japan
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan

キーワード: epidermal growth factor receptor, EGFR, tyrosine kinase inhibitor, TKI, adenosquamous, rechallenge

ジャーナルオープンアクセス

2021 年 60 巻 7 号 p. 1067-1071

DOI https://doi.org/10.2169/internalmedicine.5463-20

Browse “Advance online publication” version

詳細

抄録

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）